Aileron closes $40M financing

8 June 2009

Massachusetts, USA-based Aileron Therapeutics, a biotechnology company discovering and developing a novel class of therapeutics called stapled  peptides, says it has closed a $40.0-million series D financing. This  was co-led by new investors SR One, the independent corporate venture  fund of UK drug giant GlaxoSmithKline, and Excel Medical Fund. The round  also included major participation by existing investors: Apple Tree  Partners, who is the founding investor of Aileron, and Novartis Venture  Fund. Lilly Ventures and Roche Venture Fund also participated in the  offering.

Proceeds will be used to advance Aileron's lead stapled peptide program  toward clinical trials in 2010 and to further advance this platform and  programs in oncology, immune/ inflammation, metabolic disease, and  infectious disease. These peptides are synthetically locked, or  "stapled," into an alpha-helical shape to create drug compounds that are  uniquely effective for targets that are "undruggable" with currently  available drug approaches.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight